Procite-D^TM

Use Procite-D™ in the rebalancing process to support dopamine/catecholamines.* Inhibitory supplementation should be used prior to beginning Procite-D. Increasing catecholamine levels can suppress serotonin.

The NeuroSupport Blend™ (NSB) enhances absorption.* Improved absorption allows for smaller doses and fewer capsules.

As a potent excitatory formula, Procite-D may be recommended during the Restoration Phase of the NeuroWellness Program™ in conjunction with Adaptacin™ for balancing the function of the catecholamine pathway and strengthening the hypothalamic-pituitary-adrenal (HPA) axis.

Mucuna pruriens (standardized to 20% L-DOPA) Natural source of L-DOPA, a direct precursor to the catecholamines dopamine, norepinephrine and epinephrine.*  

DL-Phenylalanine DL-phenylalanine acts a precursor to PEA as well as the catecholamine pathway.* 

N-Acetyl-L-Tyrosine Precursor to L-DOPA, the direct precursor to the catecholamines dopamine, norepinephrine and epinephrine.* Acetylated for enhanced bioavailability. 

N-Acetyl-L-Cysteine Antioxidant.* Helps maintain cell health during catecholamine supplementation.*¹

Folate (as (6S)-5-methyl-tetrahydro folic acid, glucosamine salt) (Quatrefolic®) Cofactor in methylation reactions essential for the synthesis of dopamine, norepinephrine and epinephrine.* 

Selenium Supports selenoproteins, important antioxidant enzymes.* Selenium deficiency may contribute to decreasing dopamine levels.²

Vitamin B6 (as pyridoxal-5’-phosphate) Active form of B6. Cofactor in the conversion of L-DOPA to dopamine.* 

Vitamin B12 (as Methylcobalamin) Coenzyme form of Vitamin B12.* Methyl donor.* 

NeuroSupport Blend™ (NSB) Proprietary mixture composed of Bioperine® and plant-based enzymes clinically proven to maximize nutrient absorption.*

Serving Size: 1 Capsule
Servings Per Container: 60 Capsules

Procite-D™ Formula  435.75 mg  
Vitamin B6 (as pyridoxal-5-phosphate)
Folate (as (6S)-5-methyl-tetrahydro folic acid, glucosamine salt) (Quatrefolic®)
Vitamin B12 (as methylcobalamin)
Selenium (as L-selenomethionine)
N-Acetyl-L-Tyrosine
N-Acetyl-L-Cysteine
DL-Phenylalanine
Mucuna pruriens (std. to 20% l-Dopa) (seed)

NSB™ Proprietary Blend  102.5 mg
BioPerine® (Black Pepper Extract) (standardized to 95% piperine)(Piper nigrum) (fruit)
Protease
Amylase
Lipase

      
NSB™ is a trademark of Sanesco International Inc.

Quatrefolic® is a registered trademark of Gnosis S.p.A, U.S. Patent No. 7,947,662

BioPerine® is a registered trademark and a product of Sabinsa Corp.

Dopamine plays important roles in: 

• Motivation^3,4
  
• Impulse control^5,6
  
• Cravings, pleasure, and reward^7-10
  
• Libido^11-14

Norepinephrine contributes to: 

• Stress response^15-17
  
• Mental and emotional health (including mood) 
• Hot flashes^18-20
• Hyperactivity²¹
• Focus and cognitive function^22,23
  
• Aches and discomfort^24,25
• Aggression²⁶
• Weight management²⁷
• Energy

Epinephrine is important for: 

• Stress response^15,16,28
  
• Emotional health²⁹
  
• Blood sugar regulation^16,30
  
• Weight management^27,31,32
  

PEA contributes to: 

• Mental and emotional health^33,34
  
• Focus^34-36
  
• Fantasies and delusions³⁶
• Irregular movements³⁷
  

1. Noh J, Kim E, Kang J, et al. Experimental Neurology. 159, 217–224. 
2. Gashu, D and Stoecker BJ. Selenium and Cognition: Mechanism and Evidence. In: Preedy V., Patel V. (eds) Handbook of Famine, Starvation, and Nutrient Deprivation. Springer, Cham 2017:1-17. Accessed on August 6, 2019 https://link.springer.com/referenceworkentry/10.1007%2F978-3-319-40007-5_21-2 
3. Palmiter RD. Ann N Y Acad Sci. 2008;1129:35-46.
4. Felger JC and Treadway MT. Neuropsychopharmacology. 2017 Jan;42(1):216-241.
5. Kelley BJ, et al. Parkinsons Dis. 2012;2012:603631.
6. Athanasoulia-Kaspar AP, et al. Endocr Connect. 2018 Feb;7(2):R88-R94.
7. Blum K, et al. Curr Neuropharmacol. 2017;15(1):184-194.
8. Burger KS and Stice E. Am J Clin Nutr. 2012 Apr;95(4):810-7.
9. Stice E, et al. J Neurosci. 2010 Sep 29;30(39):13105-9.
10. Lennerz B and Lennerz JK. Clin Chem. 2018 Jan;64(1):64-71.
11. Abler B, et al. Neuropsychopharmacology. 2011 Aug;36(9):1837-47.
12. Goldstein I, et al. Mao Clin Proc. 2017 Jan;92(1):114-128.
13. Just MJ. Neuropsychiatr. Dis Treat. 2015 Jul 8;11:1655-61.
14. Stahl SM. J Clin Psychiatry. 2010 Jul;71(7):821-2.
15. Lieberman HR, et al. Physiol Behav. 2016 Oct 15;165:86-97.
16. Wong H, et al. Cureus. 2019 Aug 24;11(8):e5474.
17. Flak JN, et al. Eur J NeuroSci. 2014 Jun;39(11):1903-11.
18. Bansal R and Aggarwal N. J Midlife Health. 2019 Jan-Mar;10(1):6-13.
19. Freedman RR. Fertil Steril. 1998 Aug;70(2):332-7.
20. Gordon JL, et al. Menopause. 2016 Nov;23(11):1189-1198. 
21. Brennan AR and Arnsten AF. Ann N Y Acad Sci. 2008;1129:236-45.
22. Arnsten AF and Pliszka SR. Pharmacol Biochem Behav. 2011 Aug;99(2):211-6. 
23. Borodovitsyna O, et al. Neural Plast. 2017;2017:6031478. 
24. Ho KY, et al. Br J Anaesth. 2010 Sep;105(3):371-6.
25. Hoshino H, et al. Anesth Analg. 2015 Feb;120(2):460-6.
26. Siegel A and Victoroff J. International Journal of Law and Psychiatry. 2009;32:209–215.
27. Lee ZS, et al. Metabolism. 2001 Feb;50(2):135-43.
28. Rief W, et al. Psychosom Med. 2010 Oct;72(8):755-62.
29. Paine NJ, et al. Psychosom Med. 2015 Feb-Mar;77(2):136-44.
30. Howlett K, et al. J Physiol. 1999 Sep 15;519 Pt 3:911-21.
31. Corbi GM, et al. J Clin Endocrinol Metab. 2002 May;87(5):2080-3.
32. Couillard C, et al. Obes. Res. 2002 Jan;10(1):6-13.
33. Szabo A, et al. Br J Sports Med. 2001 Oct;35(5):342-3.
34. Kaur N and Kumari B. World J Pharm & Pharmaceut Sci. 2016 Mar;5(4):743-750.
35. Irsfeld M, et al. Webmedcentral. 2013 Sep 30;4(9). pii: 4409.
36. Kitamura T, et al. Tohoku J Exp Med. 2008 Aug;215(4):333-40.
37. Pei Y, et al. Front Neurosci. 2016 Apr 5;10:148.